The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
So there we go, people moaning about the lack of director buys and here they are.
Couldn't agree more Yesman. It was well telegraphed that there was only funding for stage 1 of phase 3 but when it is mentioned again in an update, the SP drops. Simon Thomas decides to take profits so the SP drops, the same man who tipped Cenkos before it tanked and Patisserie Valerie before it went bust. No wonder he is nervous and looking to lock in gains. Amazing how few investors have a mind of their own.
Reaction is typical in a company with so many PI. There was no new news yesterday - it was well telegraphed that there was only enough cash to get through the current study, same applies the results time line.
I reckon the drop is because a lot of PI have invested without doing any research and so have been spooked by mention of the above. Then you have a lot of people who have made a profit from the recent increases and so are cautiously crystallising that profit.
3 levels of dose on trial and a placebo. Assuming an even split, 25% of the 500 were therefore, on placebo. There has been a lot of chat on this board about the risk of the placebo effect. Interesting to know if the 20% not progressing came from the placebo/0.2% group.
Sorry, Badger not Bruce.
Not really Bruce because it is an issue of shares to subsidiary management. They have hit their earn out targets and so are getting paid as part of the acquisition deal. So very different from a run of the mill AIM con.
On track for a 4% dividend yield next year.
Strong indication all is well
Unlike funding circle this company makes money.
Said it before, rebrand as a fintech challenger and SP will go up 1000%